TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29016675
Drug: Team sport
Approvals — FDA: no, EMA: no, PMDA: no
Description: Team sport group ingesting an isocaloric drink with low protein content (3 g; TS-LP, n = 18)
Study: 25569128
Drug: Cerebral NIRS
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebral NIRS monitoring with a dedicated treatment guideline during the first 72 hours of life
Study: 23686030
Drug: Sertraline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline treatment for 5 weeks
Study: 19799601
Drug: Glycerol 855
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol 855 mg/kg
Study: 19799601
Drug: Glycerol 1710
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol 1710 mg/kg
Study: 19799601
Drug: Control (healthy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (healthy individuals) 1710 mg/kg
Study: 2891534
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg temazepam administered at 0900 h (day-time)
Study: 2891534
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg temazepam administered at 2200 h (night-time)
Study: 27527391
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) - initial dose of 1 µg/kg for 10 min followed by continuous infusion at 0.3 µg/kg/h until the end of surgery.
Study: 27527391
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - saline treatment.
Study: 22686491
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BoNT‐A) injections and abduction bracing
Study: 12002407
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement 1U/day
Study: 12002407
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement 2U/day
Study: 10202820
Drug: Ritonavir 400
Normalized name: lopinavir-ritonavir 400 mg-100 mg/5 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 400 mg twice daily and Saquinavir 400 mg twice daily, combined with Stavudine 40 mg twice daily and Lamivudine 150 mg twice daily.
Study: 10202820
Drug: Nelfinavir-containing regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir-containing regimen (previous treatment).
Study: 7717552
Drug: Fentanyl 2.5
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2.5 mcg/kg intravenous bolus followed by 1 mcg/kg/h infusion
Study: 7717552
Drug: Fentanyl 5.0
Normalized name: FENTANYL 5.0 mg in 72 h TRANSDERMAL PATCH, EXTENDED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 5.0 mcg/kg intravenous bolus followed by 2 mcg/kg/h infusion
Study: 7717552
Drug: Desflurane administration
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desflurane administration
Study: 7717552
Drug: Propofol administration
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administration
Study: 1479654
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of buprenorphine 5 micrograms.ml‐1 at 1 ml.h‐1 (group A)
Study: 1479654
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of 0.25% bupivacaine at 1 ml.h‐1 (group B)
Study: 1479654
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of buprenorphine and bupivacaine at 1 ml.h‐1 (group C)
Study: 25229216
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Sb(5+)/kg/day of intramuscular meglumine antimoniate (Sb(5+)) for 30 successive days
Study: 25229216
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment (defined as treatment applied for skin lesions less than two months old at the first appointment)
Study: 14965386
Drug: Receiving preferred
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving preferred treatment
Study: 14965386
Drug: Not receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not receiving preferred treatment
Study: 14965386
Drug: Randomised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised treatment preference
Study: 9737643
Drug: Cerivastatin 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.025 mg/day
Study: 9737643
Drug: Cerivastatin 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.05 mg/day
Study: 9737643
Drug: Cerivastatin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.1 mg/day
Study: 9737643
Drug: Lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40 mg/day (US)
Study: 9737643
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day (Europe)
Study: 9737643
Drug: Cerivastatin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.1 mg twice daily
Study: 9737643
Drug: Cerivastatin 0.2
Normalized name: cerivastatin 0.2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.2 mg with evening meal
Study: 9737643
Drug: Cerivastatin 0.2
Normalized name: cerivastatin 0.2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.2 mg at bedtime
Study: 2456776
Drug: 10% cocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% cocaine solution (3-4 ml)
Study: 23833849
Drug: Rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal misoprostol (400 micro g after spinal anesthesia)
Study: 23833849
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (after delivery of the baby)
Study: 23833849
Drug: Rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal misoprostol
Study: 18320942
Drug: perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: perioperative chemotherapy
Study: 16617756
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ropivacaine + 3.3 microg sufentanil
Study: 16617756
Drug: 6.6 mg
Normalized name: menthol 6.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.6 mg bupivacaine + 3.3 microg sufentanil
Study: 10812893
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) at 4 Hz and 8 Hz with food intake (solid meal 80 g, 135 cm3, 400 kcal)
Study: 3904243
Drug: Pirenzepine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (50 mg b.i.d)
Study: 3904243
Drug: Cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (200 mg t.i.d. + 400 mg nocte)
Study: 27568199
Drug: Ketogenic meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketogenic meal (Ketonformula®) containing 20 g of MCTs
Study: 25294887
Drug: Doxorubicin-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-based chemotherapy (CT)
Study: 22574584
Drug: Puerarin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerarin (0.5 g in 250 mL glucose injection, intravenously once daily for 14 days starting from the 3rd day)
Study: 15748091
Drug: Sivelestat (0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sivelestat (0.20 mg/kg/h)
Study: 15748091
Drug: Control (0.004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.004 mg/kg/h, effectively a placebo)
Study: 12141718
Drug: Fexofenadine 60
Normalized name: fexofenadine 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 60 mg/pseudoephedrine 120 mg
Study: 9928802
Drug: Different brands
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different brands of tape for patch tests with 2 mg/cm2 sodium dodecyl sulfate (SLS) applied for 24 hours.
Study: 7762544
Drug: Naloxone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.8 mg, s.c.)
Study: 7762544
Drug: Naloxone administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone administration in healthy subjects
Study: 7762544
Drug: Naloxone administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone administration in opiate-dependent patients
Study: 15311722
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate capsules (50 mg zinc)
Study: 9118759
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin (250 mg t.i.d.)
Study: 27146213
Drug: Brivaracetam 150-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 150-200 mg/day
Study: 25229983
Drug: Clarithromycin-based triple
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin-based triple therapy (omeprazole 20 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days)
Study: 25229983
Drug: Empirical triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical triple therapy (omeprazole 20 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days)
Study: 18753638
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus extended-release dipyridamole (ASA-ERDP) 25 mg + 200 mg twice daily
Study: 18753638
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus extended-release dipyridamole (ASA-ERDP)
Study: 12418644
Drug: Antibiotic with
Normalized name: Antibiotic with Pramoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic with protected lactobacilli
Study: 12418644
Drug: Plain antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain antibiotic (ampicillin 250 mg and cloxacillin 250 mg)
Study: 10343624
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (1500 micrograms beclomethasone daily, 1600 micrograms budesonide daily, 800 micrograms beclomethasone daily)
Study: 7555480
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (multiple daily injections (MDI) of insulin or continuous subcutaneous insulin infusion (CSII))
Study: 2037265
Drug: Cabergoline 1
Normalized name: cabergoline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 1 mg p.o. (n = 18)
Study: 2037265
Drug: Bromocriptine 5
Normalized name: bromocriptine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 5 mg/day p.o. for 14 days (n = 18)
Study: 24117655
Drug: Alcohol-related stimulant
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol-related stimulant effects
Study: 24117655
Drug: Alcohol-related sedative
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol-related sedative effects
Study: 19723863
Drug: 0.12% solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% solution chlorhexidine oral swab twice daily
Study: 19723863
Drug: Toothbrushing thrice
Normalized name: TOOTHBRUSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothbrushing thrice daily
Study: 17727664
Drug: 20% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% mannitol (1.5 g/kg)
Study: 15128353
Drug: PEG-IFN alpha2a
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFN alpha2a (180 microg/wk) and ribavirin (1-1.2 g/d) with addition of 200 mg amantadine
Study: 15128353
Drug: PEG-IFN alpha2a
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFN alpha2a (180 microg/wk) and ribavirin (1-1.2 g/d) with placebo
Study: 11490709
Drug: Categel (sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Categel (sterile gel of methylcellulose with 2% lidocaine and 0.05% chlorhexidine)
Study: 3042644
Drug: Flunarizine 10
Normalized name: flunarizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine 10 mg orally daily for three months
Study: 31594037
Drug: Upadacitinib (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib (3, 6, 12, 24 mg b.i.d. or 24 mg q.d.)
Study: 23731019
Drug: Telmisartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (80 mg for 4 weeks, then 160 mg for 20 weeks)
Study: 23878368
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg trans-resveratrol
Study: 20357044
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg trans-resveratrol
Study: 18372278
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg) plus Spironolactone (25 mg)
Study: 10579148
Drug: rBPI21 30-minute
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: rBPI21 30-minute infusion at doses of 0.25 to 4 mg/kg
Study: 10579148
Drug: rBPI21 24-
Approvals — FDA: no, EMA: no, PMDA: no
Description: rBPI21 24- to 48-hour infusion at doses of 2 to 8 mg/kg
Study: 8743521
Drug: Nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10 to 40 mg/day)
Study: 8743521
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 to 20 mg/day)
Study: 27275651
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg loading dose followed by 90 mg maintenance dose twice daily)
Study: 27275651
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg loading dose followed by 10 mg maintenance dose once daily)
Study: 25102717
Drug: Computerized injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized injection technique (CIT)
Study: 17262041
Drug: Peripheral intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral intravenous catheter (PIV)
Study: 15226470
Drug: 400 micro
Normalized name: EM 2400 Micro Volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micro g DFE/d
Study: 15226470
Drug: 800 micro
Normalized name: Fentanyl 800 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 micro g DFE/d
Study: 15226470
Drug: 135 micro
Normalized name: Lipantil Micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 micro g DFE/d (low-folate diet)
Study: 7708189
Drug: Monomeric (iohexol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monomeric (iohexol 300 mg I/ml)
Study: 7708189
Drug: Dimeric (iodixanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimeric (iodixanol 270 mg I/ml)
Study: 27363313
Drug: l-Tetrahydropalmatine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Tetrahydropalmatine (30 mg twice a day orally)
Study: 23392129
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg fluoride milk
Study: 23392129
Drug: 0.9 mg
Normalized name: estradiol 0.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg fluoride milk
Study: 11168867
Drug: Single-daily ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-daily ceftriaxone plus amikacin
Study: 11168867
Drug: Thrice-daily ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thrice-daily ceftazidime plus amikacin
Study: 8222499
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Ro 42-5892
Study: 8222499
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Ro 42-5892
Study: 8222499
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Ro 42-5892 (IV)
Study: 8222499
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Ro 42-5892 (IV)
Study: 29521247
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg twice a day for 12 weeks
Study: 20066450
Drug: Infliximab (INF)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (INF) 5 mg/Kg every 6-8 weeks
Study: 22179735
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg weekly
Study: 15591466
Drug: Fluticasone (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (125 mug, twice daily for 6 months)
Study: 2948441
Drug: Oral HD-MPA
Normalized name: polyurethane-34 (55 MPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HD-MPA (900 mg daily)
Study: 2948441
Drug: Intramuscular HD-MPA
Normalized name: polyurethane-34 (55 MPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular HD-MPA (1 g IM daily for 5 days, then 1 g twice weekly)
Study: 2948441
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and IM HD-MPA
Study: 24528605
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg (active control)
Study: 20008644
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg orally once daily
Study: 16635047
Drug: Bumetanide 0.5
Normalized name: bumetanide 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide 0.5 mg twice daily
Study: 16635047
Drug: Bumetanide >0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide >0.5 mg twice daily
Study: 16635047
Drug: Trandolapril 0.5
Normalized name: trandolapril 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 0.5 mg daily
Study: 16635047
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Bumetanide and Trandolapril)
Study: 10607943
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg melatonin p.o. daily at 2100 h for a full circadian cycle (35-71 days)
Study: 8868528
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg b.w. midazolam
Study: 24719708
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection femoral nerve block (SFNB) with 20cc ropivacaine (10mg/cc)
Study: 24719708
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia (LIA) with a combination of 300mg ropivacaine, 30mg ketorolac, and 0.5mg epinephrine diluted to 150cc
Study: 24719708
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection femoral nerve block (SFNB)
Study: 9950438
Drug: Adjuvant active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant active specific immunotherapy (ASI) with an autologous tumour cell‐BCG vaccine, three weekly vaccinations starting 4 weeks after surgery, booster vaccination at 6 months with 10(7) irradiated autologous tumour cells and 10(7) BCG organisms in the first vaccinations.
Study: 9950438
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no adjuvant treatment).
Study: 9950438
Drug: Adjuvant active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant active specific immunotherapy (ASI) specifically in stage II disease.
Study: 9950438
Drug: Adjuvant active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant active specific immunotherapy (ASI) overall.
Study: 2275326
Drug: Clonidine 4-5
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 4-5 micrograms.kg-1 p.o. in addition to pethidine 1 mg.kg-1 i.m.
Study: 2275326
Drug: Pethidine 1
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 1 mg.kg-1 i.m. (Control Group)
Study: 31363925
Drug: Healthy Activity
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy Activity Program (HAP) - a culturally adapted behavioral activation treatment
Study: 25468006
Drug: No illicit
Approvals — FDA: no, EMA: no, PMDA: no
Description: No illicit drug use (baseline negative; n = 50)
Study: 25468006
Drug: Any illicit
Normalized name: Illicium difengpi bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any illicit drug use (baseline positive; n = 75)
Study: 15353899
Drug: Mistletoe extract
Normalized name: MISTLETOE EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mistletoe extract Iscador treatment (subcutaneously for at least 3 months)
Study: 15353899
Drug: Mistletoe extract
Normalized name: MISTLETOE EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mistletoe extract Iscador treatment
Study: 11398117
Drug: Nitazoxanide 500
Normalized name: nitazoxanide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide 500 mg twice daily for 3 days (adults and adolescents)
Study: 11398117
Drug: Nitazoxanide 200
Normalized name: nitazoxanide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide 200 mg twice daily for 3 days (children aged 4-11 years)
Study: 11398117
Drug: Nitazoxanide 100
Normalized name: nitazoxanide 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide 100 mg twice daily for 3 days (children aged 1-3 years)
Study: 21907749
Drug: MVA-B (1×10(8)
Normalized name: amphotericin B 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-B (1×10(8) pfu/dose) administered as 3 intramuscular injections at weeks 0, 4, and 16
Study: 21907749
Drug: MVA-B (1×10(8)
Normalized name: amphotericin B 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-B (1×10(8) pfu/dose)
Study: 10700784
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 1.25 mg and fentanyl 25 micrograms (group A)
Study: 10700784
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 2.5 mg and fentanyl 25 micrograms (group B)
Study: 7537364
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate therapy